U.S. markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
54.17-0.91 (-1.65%)
At close: 4:00PM EDT

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
49 7071 9883 0

Full Time Employees455

Key Executives

NameTitlePayExercisedYear Born
Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.CEO & Member of Management Board708.5kN/A1970
Mr. Pierre Kemula B.Sc.MD, CFO & Member of Management Board689.22kN/A1974
Ms. Mariola Fotin-MleczekCTO & Member of Management Board551.17kN/A1968
Ms. Ulrike Gnad-Vogt Ph.D., M.D.Interim Chief Devel. Officer & Member of Exec. Board416.98kN/A1972
Dr. Igor Splawski M.Sc., Ph.D.Chief Scientific Officer & Member of Management Board464.56kN/A1969
Dr. Antony BlancMD, Chief Bus. Officer & Chief Commercial Officer420.16kN/A1969
Dr. Klaus Edvardsen M.D., Ph.D.Managing DirectorN/AN/AN/A
Mr. Malte Greune Ph.D.COO & Member of Management BoardN/AN/AN/A
Dr. Sarah FakihVP Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Thorsten SchullerHead of Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate Governance

CureVac N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.